The Enhertu effect: Daiichi’s plan to build on the success of its crown jewel
Right now is “singularly, the most exciting moment” in Daiichi Sankyo’s 100-year history, said Ken Keller, CEO and president of the company’s U.S. business and head of its global oncology unit. Riding high from the success of the AstraZeneca-partnered …